ERBB2 and neoplasm: Interestingly, when we matched serological and tumor monitoring data in groups of mice clustered according to CTX + ACT/IS efficacy (Supplementary Figure S4), we found that the amount of anti-Neu antibodies was highest in the group of mice experiencing a complete and long-lasting response (group 1), while anti-Neu Ab levels were progressively lower in mice showing relapses or partial response (groups 2 and 3).